PetMed Express, Inc. D/B/A 1-800-PetMeds Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares Its $0.27 Per Share Dividend


DELRAY BEACH, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the fiscal year ended March 31, 2019.  Net sales for the quarter ended March 31, 2019 were $64.6 million, compared to $67.3 million for the quarter ended March 31, 2018, a decrease of 4.1%.  For the fiscal year ended March 31, 2019 net sales were $283.4 million, compared to $273.8 million for the fiscal year ended March 31, 2018, an increase of 3.5%.  Reorder sales for the fiscal year ended March 31, 2019 were $241.8 million, compared to $227.5 million for the year ended March 31, 2018, an increase of 6.3%.  Net income for the quarter ended March 31, 2019 was $6.6 million, or $0.32 diluted per share, compared to net income of $10.2 million, or $0.50 diluted per share, for the same quarter the prior year, a decrease to net income of 35%.  Net income for the fiscal year ended March 31, 2019 was $37.7 million, or $1.84 diluted per share, compared to net income of $37.3 million, or $1.82 diluted per share, for the fiscal year ended March 31, 2018, an increase to net income of 1.2%.  The Company’s online sales for the fiscal year ended March 31, 2019 were approximately 85% of all sales, compared to 84% for the prior year.

Menderes Akdag, President and CEO, commented: “The online pet medication market continued to be more competitive during the quarter, which had a negative effect on our sales and gross margins. Our average order value was $87 for both fiscal 2019 and 2018. Net cash provided by operating activities improved to $45.1 million for fiscal 2019 compared to $37.4 million for fiscal 2018. In fiscal 2020, we will continue to be price competitive, and will increase advertising to promote brand awareness and reinforce brand loyalty to address this more competitive online market. In addition, we will be investing in our e-commerce platform to better service our customers.”

The Board of Directors declared a quarterly dividend of $0.27 per share on its common stock.  The dividend will be payable on May 24, 2019, to shareholders of record at the close of business on May 17, 2019.  The Company intends to continue to pay regular quarterly dividends; however the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.

This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the year-end financial results.  To access the call which is open to the public, dial (888) 455-1758 (toll free) or (203) 827-7025.  Callers will be required to supply PETMEDS as the passcode.  For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. Eastern Time on May 6, 2019 until May 20, 2019 at 11:59 P.M.  To access the replay, call (866) 465-0340 (toll free) or (203) 369-1417 and enter passcode 5500.

Founded in 1996, PetMed Express is America’s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.  This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan.  Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2018.  The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.

For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except for per share amounts)
  March 31, March 31,
  2019 2018
     
ASSETS (UNAUDITED)  
     
Current assets:    
Cash and cash equivalents$  100,529$  77,936
Accounts receivable, less allowance for doubtful
  accounts of $39 and $35, respectively
   2,542   2,292
Inventories - finished goods   21,370   23,337
Prepaid expenses and other current assets   1,408   882
Prepaid income taxes   582   788
Total current assets   126,431   105,235
     
Noncurrent assets:    
Property and equipment, net   27,136   28,741
Intangible assets   860   860
Total noncurrent assets   27,996   29,601
     
Total assets$  154,427$  134,836
     
LIABILITIES AND SHAREHOLDERS' EQUITY    
     
Current liabilities:    
Accounts payable$  16,275$  15,274
Accrued expenses and other current liabilities   2,351   2,835
Total current liabilities   18,626   18,109
     
Deferred tax liabilities   1,121   996
     
Total liabilities   19,747   19,105
     
Commitments and contingencies    
     
Shareholders' equity:    
Preferred stock, $.001 par value, 5,000 shares authorized;    
3 convertible shares issued and outstanding with a
liquidation preference of $4 per share
   9   9
Common stock, $.001 par value, 40,000 shares authorized;    
20,674 and 20,601 shares issued and outstanding, respectively   21   21
Additional paid-in capital   12,478   9,381
Retained earnings   122,172   106,320
     
Total shareholders' equity   134,680   115,731
     
Total liabilities and shareholders' equity$  154,427$  134,836
     

 

 PETMED EXPRESS, INC. AND SUBSIDIARIES 
 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 
 (In thousands, except for per share amount) 
         
   Three Months Ended   Year Ended 
   March 31,   March 31, 
  2019 2018 2019 2018
         
   (UNAUDITED)   (UNAUDITED)   
Sales  $   64,565 $   67,322 $   283,419 $   273,800
Cost of sales    43,841   42,403   188,105   175,993
         
Gross profit    20,724   24,919   95,314   97,807
         
Operating expenses:         
General and administrative    5,840   6,068   24,767   24,290
Advertising    6,522   4,311   22,148   19,255
Depreciation    560   536   2,225   2,126
Total operating expenses    12,922   10,915   49,140   45,671
         
Income from operations    7,802   14,004   46,174   52,136
         
Other income:         
Interest income, net    549   241   1,864   658
Other, net    256   240   1,083   995
Total other income    805   481   2,947   1,653
         
Income before provision for income taxes    8,607   14,485   49,121   53,789
         
Provision for income taxes    1,987   4,302   11,381   16,506
         
Net income  $   6,620 $   10,183 $   37,740 $   37,283
         
Comprehensive income  $   6,620 $   10,183 $   37,740 $   37,283
         
Net income per common share:         
Basic  $   0.32 $   0.50 $   1.84 $   1.83
Diluted  $   0.32 $   0.50 $   1.84 $   1.82
         
Weighted average number of common shares outstanding:       
Basic    20,491   20,375   20,461   20,346
Diluted    20,501   20,422   20,491   20,433
         
 Cash dividends declared per common share  $   0.27 $   0.25 $   1.06 $   0.85

 

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
   Year Ended 
   March 31, 
  2019  2018 
  (UNAUDITED)  
Cash flows from operating activities:     
Net income  $   37,740  $   37,283 
Adjustments to reconcile net income to net cash
  provided by operating activities: 
    
Depreciation    2,225    2,126 
Share based compensation    3,097    2,575 
Deferred income taxes    125    (92)
Bad debt expense    85    112 
(Increase) decrease in operating assets
  and increase (decrease) in liabilities: 
    
Accounts receivable    (335)   (596)
Inventories - finished goods    1,967    (3,109)
Prepaid income taxes    206    (788)
Prepaid expenses and other current assets    (526)   137 
Accounts payable    1,001    53 
Accrued expenses and other current liabilities    (447)   337 
Income taxes payable    -     (659)
Net cash provided by operating activities    45,138    37,379 
     
Cash flows from investing activities:     
Purchases of property and equipment    (620)   (703)
Net cash used in investing activities    (620)   (703)
     
Cash flows from financing activities:     
Dividends paid    (21,925)   (17,470)
Net cash used in financing activities    (21,925)   (17,470)
     
Net increase in cash and cash equivalents    22,593    19,206 
     
Cash and cash equivalents, at beginning of year    77,936    58,730 
     
Cash and cash equivalents, at end of year  $   100,529  $   77,936 
     
Supplemental disclosure of cash flow information:     
     
Cash paid for income taxes  $   11,051  $   18,046 
     
Dividends payable in accrued expenses  $   203  $   240